A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
PEX168 or placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring PEX168, Phase I/II, add on to metformin
Eligibility Criteria
Inclusion Criteria:
- Has been diagnosed with type 2 diabetes mellitus.
- Has been treated with a stable dose of metformin monotherapy ≥ 12 weeks before randomization, and metformin dose ≥ 1500 mg / day.
- Has HbA1c of 7.5% to 11.0%(local) at screening. And has HbA1c of 7.0% to 11.0%(Central) before randomization.
- Is 20 to 70 years old, inclusive.
- Has a body mass index (BMI) of 19 kg/m2 to 35 kg/m2, inclusive.
Exclusion Criteria:
- Skin test of PEX168 is positive.
Is currently treated with any of the following excluded medications:
- GLP-1 or GLP-1 analogues prior to study start;
- Insulin within 6 months prior to study start;
- Growth hormone within 6 months prior to study start;
- Abuse of drug or alcohol within 6 months prior to study start;
- Any other hypoglycemic drugs (including Chinese herbal medicine) except for metformin within 3 months prior to study start;
- Any clinical trials of drugs or medical instruments within 3 months prior to study start;
- Systemic corticosteroids by oral, parenteral, or intra-articular route
- Any drugs for weight loss or operations leading to weight instable within 2 months prior to study start;
- Any drugs that may interfere the evaluation of safety and efficiency of investigated drugs, drugs or herbals medicine that may result in toxicity to main organs prior to study start;
A history or evidence of any of the following :
- Severe hypoglycemia history (e.g., sleepiness, consciousness disorder, deliration, coma led by hypoglycemia);
- Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes (e.g., Cushing's syndrome or acromegaly-associated diabetes);
- Acute or chronic gastrointestinal diseases that were not suitable for the trials evaluated by investigators;
- Hypertension with SBP>140mmHg, and/or DBP >90mmHg after antihypertensive therapy;
- Severe cardiovascular diseases histories including congestive heart failure (NYHA III or IV), unstable angina, stroke or TIA, myocardial infarction,sustained and clinically relevant ventricular arrhythmia, coronary artery bypass surgery or percutaneous coronary intervention;
- Acute or chronic pancreatitis history, or pancreas injury history, or any high risk factors which may result in pancreatitis;
- Malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, regardless of whether there is evidence of local recurrence or metastases;
- Medullary thyroid carcinoma history, or multiple endocrine neoplasia history;
- Acute metabolic complications such as ketoacidosis, lactic acidosis, or hyperosmolar state (coma) , or maculopathy , or instability of proliferative retinopathy within the past 6 months;
- Weight change is over 10% within 3 months prior to the study start;
Any of the following significant laboratory abnormalities:
- Alanine aminotrasferase (ALT) and/or asparatate aminotransferase (AST)>2*upper limit of normal (ULN), and/or total bilirubin>1.5*ULN, confirmed by repeat measure;
- Creatinine > upper limit of normal, confirmed by repeat measure, and/or proteinurea>++ and 24 hour urinary protein quantitative ≥1g;
- Fasting plasma triglyceride ≥ 5.64 mmol/L (500mg/dL);
- Thyroid dysfunction unsuitable for this trial evaluated by investigator;
- Hemodlastase > upper limit of normal, confirmed by repeat measure;
- Male or female fertility are reluctant to take contraceptive method during the test, pregnancy or lactating women;
- Any other situations which may result in the withdrawal of subjects or bring significant risk to subjects.
Sites / Locations
- China-Japan Friendship Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
PEX168 100 microgram
PEX168 200 microgram
Placebo
Arm Description
PEX168 100 microgram qw sc. and the medication continued for 12 weeks
PEX168 200 microgram qw sc. and the medication continued for 12 weeks
Placebo qw sc. and the medication continued for 12 weeks
Outcomes
Primary Outcome Measures
To assess HbA1C levels after treatment
Secondary Outcome Measures
To assess Fasting blood glucose levels
Full Information
NCT ID
NCT01965509
First Posted
June 12, 2013
Last Updated
October 15, 2013
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
China-Japan Friendship Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01965509
Brief Title
A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Official Title
A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 12 Weeks Injection of Polyethylene Glycol Loxenatide Add to Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
October 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
China-Japan Friendship Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).
This study aims to evaluate the effective therapeutic concentration range of PEX168, also decided to observe safety and PK/PD correlation by long-term continuous administration.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
PEX168, Phase I/II, add on to metformin
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PEX168 100 microgram
Arm Type
Experimental
Arm Description
PEX168 100 microgram qw sc. and the medication continued for 12 weeks
Arm Title
PEX168 200 microgram
Arm Type
Experimental
Arm Description
PEX168 200 microgram qw sc. and the medication continued for 12 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo qw sc. and the medication continued for 12 weeks
Intervention Type
Drug
Intervention Name(s)
PEX168 or placebo
Other Intervention Name(s)
Polyethylene Glycol Loxenatide or Placebo
Intervention Description
injection has to administered subcutaneously weekly
Primary Outcome Measure Information:
Title
To assess HbA1C levels after treatment
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
To assess Fasting blood glucose levels
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
To assess the body weights after the treatment
Time Frame
12 weeks
Title
To assess number of participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Has been diagnosed with type 2 diabetes mellitus.
Has been treated with a stable dose of metformin monotherapy ≥ 12 weeks before randomization, and metformin dose ≥ 1500 mg / day.
Has HbA1c of 7.5% to 11.0%(local) at screening. And has HbA1c of 7.0% to 11.0%(Central) before randomization.
Is 20 to 70 years old, inclusive.
Has a body mass index (BMI) of 19 kg/m2 to 35 kg/m2, inclusive.
Exclusion Criteria:
Skin test of PEX168 is positive.
Is currently treated with any of the following excluded medications:
GLP-1 or GLP-1 analogues prior to study start;
Insulin within 6 months prior to study start;
Growth hormone within 6 months prior to study start;
Abuse of drug or alcohol within 6 months prior to study start;
Any other hypoglycemic drugs (including Chinese herbal medicine) except for metformin within 3 months prior to study start;
Any clinical trials of drugs or medical instruments within 3 months prior to study start;
Systemic corticosteroids by oral, parenteral, or intra-articular route
Any drugs for weight loss or operations leading to weight instable within 2 months prior to study start;
Any drugs that may interfere the evaluation of safety and efficiency of investigated drugs, drugs or herbals medicine that may result in toxicity to main organs prior to study start;
A history or evidence of any of the following :
Severe hypoglycemia history (e.g., sleepiness, consciousness disorder, deliration, coma led by hypoglycemia);
Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes (e.g., Cushing's syndrome or acromegaly-associated diabetes);
Acute or chronic gastrointestinal diseases that were not suitable for the trials evaluated by investigators;
Hypertension with SBP>140mmHg, and/or DBP >90mmHg after antihypertensive therapy;
Severe cardiovascular diseases histories including congestive heart failure (NYHA III or IV), unstable angina, stroke or TIA, myocardial infarction,sustained and clinically relevant ventricular arrhythmia, coronary artery bypass surgery or percutaneous coronary intervention;
Acute or chronic pancreatitis history, or pancreas injury history, or any high risk factors which may result in pancreatitis;
Malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, regardless of whether there is evidence of local recurrence or metastases;
Medullary thyroid carcinoma history, or multiple endocrine neoplasia history;
Acute metabolic complications such as ketoacidosis, lactic acidosis, or hyperosmolar state (coma) , or maculopathy , or instability of proliferative retinopathy within the past 6 months;
Weight change is over 10% within 3 months prior to the study start;
Any of the following significant laboratory abnormalities:
Alanine aminotrasferase (ALT) and/or asparatate aminotransferase (AST)>2*upper limit of normal (ULN), and/or total bilirubin>1.5*ULN, confirmed by repeat measure;
Creatinine > upper limit of normal, confirmed by repeat measure, and/or proteinurea>++ and 24 hour urinary protein quantitative ≥1g;
Fasting plasma triglyceride ≥ 5.64 mmol/L (500mg/dL);
Thyroid dysfunction unsuitable for this trial evaluated by investigator;
Hemodlastase > upper limit of normal, confirmed by repeat measure;
Male or female fertility are reluctant to take contraceptive method during the test, pregnancy or lactating women;
Any other situations which may result in the withdrawal of subjects or bring significant risk to subjects.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wenying Yang, M.D
Organizational Affiliation
China-Japan Friendship Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
China-Japan Friendship Hospital
City
Beijing
Country
China
12. IPD Sharing Statement
Learn more about this trial
A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs